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ABSTRACT
Previous clinical reports have found elevated osteopontin (OPN) levels in tumor 
tissues to be indicative of greater malignancy in human hepatocellular carcinoma 
(HCC). However, the role of OPN on carcinogenesis and its underlying mechanism 
remain unclear. In the present study, we investigated the oncogenic role of OPN 
in diethylnitrosamine (DEN)-induced hepatic carcinogenesis in mice. The overall 
incidence of hepatic tumors at 36 weeks was significantly lower in OPN knockout 
(KO) mice than in wild-type (WT) mice. Apoptosis was significantly enhanced in OPN 
KO mice, and was accompanied by the downregulation of epidermal growth factor 
receptor (EGFR). In the in vitro study, OPN suppression also led to lower mRNA and 
protein levels of EGFR associated with the downregulation of c-Jun in Hep3B and Huh7 
human HCC cells lines, which resulted in increased apoptotic cell death in both cell 
lines. Moreover, a positive correlation was clearly identified between the expression of 
OPN and EGFR in human HCC tissues. These data demonstrate that the OPN deficiency 
reduced the incidence of chemically induced HCC by suppressing EGFR-mediated anti-
apoptotic signaling. An important implication of our findings is that OPN positively 
contributes to hepatic carcinogenesis.
INTRODUCTION
Liver cancer is the second most common cause of 
cancer-related death, and its incidence and mortality are 
prominent in East Asia, including Korea, Japan, and China 
[1]. Many studies have determined that various etiologies, 
including chronic hepatitis B or C viral infection and 
cirrhosis are important risk factors for HCC [2, 3]. Each 
factor or combination of these factors can give rise to an 
inflammatory response and DNA damage, which progress 
through chronic hepatitis, cirrhosis, and eventually HCC 
[4–6]. Nagoshi established that HCC-associated liver 
disease were strongly associated with the expression of 
OPN in various cells, including hepatocytes, Kupffer cells, 
and stellate cells [7].
OPN is a secreted glycophosphoprotein that acts 
a ligand for its receptors, including integrins and CD44 
variants, and the interactions between OPN and its 
receptors promote a variety of signaling pathways that 
eventually result in tumor progression [8]. Clinical reports 
have found that a range of tumor tissues showed higher 
OPN expression than adjacent normal tissue [9, 10]. 
Likewise, it is accepted that OPN plays a crucial role in 
the oncogenesis of HCC, and that OPN overexpression is 
positively correlated with tumor progression [7]. Zhang 
et al. established that the binding of OPN to integrin and 
CD44 activated MMP-2, resulting in greater invasiveness 
[11]. In addition, HCC patients displaying the elevated 
expression of OPN mRNA in tumor tissues had a higher 
risk of intrahepatic metastasis and early recurrence [12]. 
Based on above findings, it is reasonable to conclude that 
OPN is a candidate biomarker and target for HCC therapy.
EGFR is a transmembrane growth factor 
regulated by receptor dimerization, which could be 
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transactivated by OPN. The transactivation of EGFR 
principally upregulates the mitogen-activated protein 
kinase (MAPK), signal transducer and activator of 
transcirption (STAT) 3 and phosphoinositide 3-kinase/
Akt signaling pathways [13, 14]. Although EGFR is 
essential in the regulation of normal development and 
cell differentiation, it has been proposed that EGFR 
activation may be tightly linked with the carcinogenesis 
of solid tumors [15–17]. Moreover, Harada et al. found 
that cirrhotic liver tissue and HCC tumor tissue tended 
to show EGFR overexpression [18].
Over the past decades, several reports have 
demonstrated that OPN overexpression in tumor tissues 
indicate more advanced tumor stages in human HCC, and 
that OPN is a viable marker for determining the prognosis, in 
combination with other factors [19–21]. However, the role of 
OPN on tumor development and the underlying mechanism 
remain poorly understood. In this study, we assessed how 
OPN deficiency affected liver carcinogenesis in vivo through 
a DEN-induced mouse HCC model and in vitro using human 
HCC cell lines, with the result that OPN was overexpressed 
in the tumor tissue in human HCC samples. We found that 
OPN played an oncogenic role in DEN-induced hepatic 
carcinogenesis, accompanied by the upregulation of EGFR.
RESULTS
Lack of OPN suppresses DEN-induced hepatic 
carcinogenesis
Macroscopically, the nodules displayed protruding 
single-to-multiple polypoid patterns in both the WT and 
OPN KO mice at 36 weeks after DEN injection. The 
properties of the nodules are summarized in Table 1. 
The size of the nodules in the OPN KO mice (1.2 ± 0.2 
mm) was significantly smaller than that of WT mice (7.3 
± 1.8 mm; P<0.01), although the multiplicity was not 
significantly different between OPN KO mice (3.9 ± 0.9) 
and the WT mice (4.9 ± 1.3).
A histological analysis at 36 weeks after DEN 
injection showed a significantly lower prevalence of 
liver tumors in the OPN KO mice (14.3%) than in 
the WT mice (61.5%; P<0.05), and two of the eight 
tumor-bearing WT mice exhibited HCC (15.4%). 
Microscopically, the neoplastic nodules from the OPN 
KO mice at 36 weeks were sharply demarcated and 
consisted of well-differentiated neoplastic cells exhibiting 
trabecular patterns (Figure 1A). WT mice at 36 weeks 
showed similar histologic pattern but larger neoplastic 
nodules bulging from the capsular surface (Figure 1A). 
Meanwhile, HCC from WT mice at 36 weeks consisted of 
poorly differentiated neoplastic cells showing solid growth 
pattern with irregular border (Figure 1A). In contrast, OPN 
KO mice at 26 weeks after DEN injection showed a 13.3% 
incidence rate of hepatocellular adenoma, whereas WT 
mice did not have liver tumors at this time point, although 
this tendency was not found to be statistically significant. 
The neoplastic nodules from the OPN KO mice at 26 
weeks showed similar histopathological features to 
nodules from the OPN KO mice at 36 weeks (Figure 1A).
OPN expression is increased in human HCC 
tissue samples
Based on our results, we performed IHC for OPN 
in tumor-bearing WT mice, and six of the eight WT 
mice demonstrated a significantly higher degree of OPN 
expression in the cytoplasm of tumor cells compared to 
adjacent normal areas (P<0.01; Figure 1Ba–1b and 1C). 
Although this observation was based on only two cases, 
the degree of OPN expression was stronger in carcinomas 
than in adenomas (Figure 1Ba–1b).
We also carried out IHC for OPN in eight cases of 
human HCC. Similarly to the mouse results, seven of the 
eight cases showed higher OPN expression (Figure 1Bc–
1d). Tumor tissue from those seven cases showed diffuse 
and moderate to strong OPN expression in the cytoplasm 
of tumor cells, whereas OPN expression was rarely or 
weakly observed in the paired non-tumor tissue (P<0.001; 
Figure 1Bc–d and 1C). In particular, tumor cells located 
on the boundary of tumor tissue prominently expressed 
OPN in all eight cases (Figure 1Bd).
OPN depletion promotes apoptotic cell death in 
mouse liver
Next, we characterized the effect of OPN on 
apoptotic cell death in mouse liver tissue. Compared with 
WT mice at 26 weeks after DEN injection, non-tumor 
tissue from OPN KO mice showed a greater number of 
TUNEL-positive apoptotic hepatocytes (Figure 2A and 
2B). In tumor tissue from mice at 36 weeks after DEN 
injection, the apoptotic index was considerably higher in 
the OPN KO mice than WT mice (Figure 2A and 2B). 
The extent of apoptotic cell death in non-tumor tissue from 
OPN KO mice was also greater than in the corresponding 
samples obtained from WT mice (Figure 2A and 2B). 
These results suggest that increased apoptosis in normal 
hepatocytes and in tumor cells of OPN KO mice may 
inhibit hepatic carcinogenesis.
OPN increases cell viability through the 
inhibition of apoptotic cell death
As observed in mouse liver tissue, OPN is 
hypothesized to have a negative effect on apoptotic cell 
death. In order to investigate the effect of OPN on cell 
viability and apoptosis in human HCC, we compared 
growth rates between control and OPN KD Hep3B 
and Huh7. After incubation for 24 hours, the OPN KD 
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Hep3B and Huh7 showed a lower number of cells than 
the control cells did, and the growth rate differential 
was more prominent at 48 hours in the Hep3B cells 
(Figure 3A).
Furthermore, rhOPN treatment of OPN KD Hep3B 
and Huh7 at 12 hours after seeding restored cell viability 
to a similar degree as observed in control cells (Figure 
3B). Accordingly, treatment of OPN antibody on control 
Hep3B and Huh7 decreased cell viability, but not to a 
significant extent (Figure 3B). In order to clarify the role 
of OPN in cell viability, we also carried out an annexin 
V assay and a TUNEL assay. The increased proportion 
of early apoptotic cells in OPN KD Hep3B and Huh7 
diminished in rhOPN-treated OPN KD Hep3B and Huh7 
(Figure 3C). The TUNEL assay results also indicated that 
rhOPN treatment reduced apoptotic cell death in OPN KD 
Hep3B and Huh7 (Figure 4A). However, supplemental 
OPN antibody to control Hep3B and Huh7 had relatively 
minimal effect on early and late apoptosis in the annexin 
V assay (Figure S2A)
Consistent with the TUNEL assay results, OPN 
KD Hep3B and Huh7 showed lower expression levels 
of anti-apoptotic proteins (Bcl-xL and Bcl-2) and higher 
expression levels of pro-apoptotic proteins (cleaved 
PARP-1, caspase 9, and caspase 3) than control cells 
(Figure 4B). However, the expression levels of these 
proteins in the OPN KD Hep3B and Huh7 were 
similar to those observed in control cells following 
rhOPN treatment (Figure 4B). Although the changes 
of apoptotic cell death in the annexin V assay were 
not remarkable, the expression levels of pro-apoptotic 
proteins (cleaved PARP-1 and caspase 3) in Hep3B and 
Huh7 were increased by the incubation with the OPN 
antibody (Figure S2B).
OPN upregulates EGFR expression and related 
signaling pathways
We then investigated the mRNA and protein levels 
of EGFR and related molecules depending on OPN 
expression. IHC demonstrated that WT mice at 36 weeks 
after DEN injection showed extensive EGFR expression in 
the cellular membranes, while weakly positive expression 
was observed in OPN KO mice (Figure 5A). In vitro, the 
mRNA level of EGFR and the protein level of nuclear 
c-Jun were significantly decreased by OPN suppression 
in the Hep3B and Huh7 (Figure 5B). Likewise, EGFR, 
phosphorylated ERK1 expression in OPN KD Hep3B 
and Huh7 were lower than was observed in control 
cells (Figure 5C). The expression levels of EGFR and 
phosphorylated ERK in OPN KD Hep3B and Huh7 were 
increased by supplemental rhOPN in a time-dependent 
manner (Figure 5D).
OPN expression is positively correlated with 
EGFR expression in human HCC tissue
EGFR expression showed a significant positive 
correlation with OPN expression in HCC (P<0.01, 
r=0.3567; Figure 6B). In cases where OPN expression was 
moderate or strongly positive, 85.3% (29/34) exhibited 
moderately or strongly positive expression of EGFR 
(Figure 6A and 6B). Conversely, in the 24 cases showing 
negative or weakly positive expression of OPN, negative 
or weakly positive expression of EGFR was observed in 
15 cases (62.5%) (Figure 6A and 6B).
We also found that the degree of OPN expression 
was correlated with the pTNM stage (P<0.05; Figure 6B). 
More than half of the samples displayed a negative or 





















WT Yes 26 14 0 0 0 0 0
KO Yes 26 15 2/15 (13.3) 2/15 (13.3) 0 1.7 ± 0.5 0.8 ± 0.3
WT No 26 7 0 0 0 0 0
KO No 26 7 0 0 0 0 0
WT Yes 36 13 8/13 (61.5) 8/13 (61.5) 2/13 (15.4) 4.9 ± 1.3 7.3 ± 1.8
KO Yes 36 14 2/14 (14.3) * 2/14 (14.3) 0 3.9 ± 0.9 1.2 ± 0.2 **
WT No 36 7 0 0 0 0 0
KO No 36 7 0 0 0 0 0
Data are presented as means±SEMs. *P < 0.05 and **P < 0.01 versus WT mice.
OPN, osteopontin; DEN, diethylnitrosamine; WT, wild-type; KO, knockout
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weakly positive expression of OPN in stage I or II patients 
(Figure 6B); however, moderate to strongly positive 
expression of OPN was observed in 66.7% and 80% of 
stage III and IV samples, respectively (Figure 6B).
DISCUSSION
In the past decades, OPN has been found to play 
an important role in oncogenic processes contributing to 
HCC and liver cirrhosis [22, 23]. Huang et al. showed 
that plasma OPN levels were positively correlated with 
hepatitis C virus infection and the grades of hepatic 
inflammation and fibrosis in human patients [24]. A 
previous study found that nonalcoholic steatohepatitis-
related cirrhosis was increased by Hedgehog pathway-
mediated OPN overexpression [25]. In the present study, 
we focused on the effect of OPN on the development 
of chemically induced HCC and the underlying 
mechanism involving apoptosis. We showed that hepatic 
carcinogenesis was considerably inhibited by OPN 
deficiency at 36 weeks, accompanied by the increase 
of apoptotic cell death in OPN KO mice. Meanwhile, 
OPN KO mice at 26 weeks showed the development of 
hepatocellular adenoma in 2/15 mice, whereas WT mice 
had no tumors; there were no statistical significance. In 
comparison with the incidence of tumor at 26 weeks, no 
increase of tumor incidence at 36 weeks was observed 
in OPN KO mice, 8/13 WT mice had hepatocellular 
adenoma and carcinoma. Based on these results, tumor 
development and progression worsened by OPN. OPN 
expression was prominent in the tumor tissue of WT 
mice, whereas adjacent liver tissue rarely showed OPN 
expression. Similarly, strong OPN expression was noted in 
most of human HCC samples. These results correspond to 
previous clinical studies that found OPN overexpression to 
be positively correlated with tumor progression.
Apoptosis is an essential process for maintaining 
homeostasis in normal tissue, and is connected with 
carcinogenesis because tumor cells may be able to evade 
apoptotic stimuli [26]. In a previous study, we suggested 
that OPN protected gastric epithelial cells and cancer cells 
from inducible nitric oxide synthase-mediated apoptosis 
through STAT1 downregulation, thereby promoting the 
development and progression of gastric cancer [27]. 
Likewise, some studies have reported that OPN played an 
important role in inhibiting apoptosis [28, 29]. In a mouse 
Figure 1: Histopathology and IHC for OPN. A. Hematoxylin and eosin staining in liver tissue samples from tumor-bearing WT and 
OPN KO mice. The boxed regions of the left panels in the WT and OPN KO samples are shown at higher magnification in the right panels. 
The nodules from the OPN KO mice at 26 and 36 weeks were sharply circumscribed and composed of well-differentiated tumor cells or 
vacuolated cells that formed trabeculae or nests, whereas the nodules from the WT mice at 36 weeks showed a sessile and solid growth 
pattern. B, C. IHC and quantification for OPN in mouse and human liver tissue samples. The tumor tissue samples (T) showed greater 
cytoplasmic expression of OPN than non-tumor tissue sample (NT) in both mouse (a, b) and human (c, d) samples. In mice, hepatocellular 
carcinoma (b) displayed more prominent OPN expression than hepatocellular adenoma (a). **P < 0.01 or ***P < 0.001 versus non-tumor 
tissue samples.
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model, Hsieh et al. found that OPN deficiency promoted 
apoptosis and delayed the development of squamous 
papilloma [30]. In addition, it has been demonstrated 
through IHC that the anti-apoptotic effect of OPN may be 
related to the regulation of nuclear factor-kappa B (NF-
κB) expression in human renal cell carcinoma [31]. In 
accordance with these results, we demonstrated that the 
tumor tissue samples and non-tumor tissue samples of 
OPN KO mice displayed a higher apoptotic index than 
was observed in WT mice, and that OPN suppression in 
human HCC cells also promoted apoptotic cell death. 
Previous studies have shown that OPN has two isoforms: 
a secreted form (sOPN) and an intracellular form (iOPN), 
generated by alternative translation [32]. Based on the 
Figure 2: Apoptotic cell death in mouse liver tissue samples. A. Representative photomicrographs of total cells and TUNEL-
positive cells in the liver tissue of DEN-treated-WT and OPN KO mice. The apoptotic index in non-tumor tissue of OPN KO mice at 26 
weeks was considerably higher than that observed in WT mice. At 36 weeks, OPN KO mice also showed significantly larger numbers of 
apoptotic cells in non-tumor and tumor tissue samples than WT mice. B. Results are presented as means ± SEMs (n=3–4 for non-tumor 
tissue from WT and OPN KO mice, n=3–4 for tumor tissue from WT mice and n=2 for tumor tissue from OPN KO mice). **P < 0.01 
versus WT mice.
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observation that the supplemental provision of rhOPN to 
OPN KD human HCC cells inhibited apoptosis, and that 
OPN overexpression in cells rarely affect cell viability 
and apoptotic cell death in the present study, it may be 
hypothesized that the anti-apoptotic effect of OPN is due 
to sOPN rather than iOPN (Figure S3A and SB). Some 
reports support the possibility that the role of OPN in 
apoptotic cell death is mediated by interactions between 
OPN and its surface receptors with related downstream 
signaling. Zhao et al. previously found that OPN 
downregulation led to the inhibition of integrin expression, 
which could block the activity of NF-κB [33]. In addition, 
binding to the CD44 variants was able to exert significant 
suppressive effects on apoptosis of tumor cells through 
the phosphoinositide 3-kinase/Akt pathway [34]. Our 
data suggest that the increased apoptosis of hepatocytes 
and tumor cells may cause the suppression of hepatic 
carcinogenesis in OPN KO mice.
Next, we evaluated EGFR expression according 
to OPN regulation in order to explore the underlying 
mechanism through which OPN suppresses apoptosis. It 
has been confirmed that EGFR and downstream signaling 
significantly contribute to the carcinogenesis of various 
epithelial cancers [35, 36]. Similarly, EGFR blockade 
Figure 3: Effect of OPN downregulation on cell viability. A. The cell viability of Hep3B and Huh7 at each time point. OPN 
KD Hep3B and Huh7 at 24 hours showed lower cell viability than control cells, and the cell viability of Hep3B was also decreased by 
OPN suppression at 48 hours. # The cell viability of Huh7 at 48 hours was not assessed due to saturation. Results are presented as SEMs 
(n=6 for each time point, three independent experiments). B. Changes in cell viability according to treatment with OPN antibody (Ab) or 
recombinant human OPN (rhOPN). The blockade of secreted OPN by OPN Ab in control cells caused a decrease of cell viability, although 
statistical significance was not observed. Supplemental rhOPN in OPN KD Hep3B and Huh7 considerably increased cell viability in both 
cell lines. The results are presented as means ± SEMs (n=6 for each condition, three independent experiments). C. Assessment of apoptotic 
cell death. Early and late apoptosis (lower and upper right quadrants) were more frequently observed in OPN KD Hep3B and Huh7. 
Supplemental rhOPN in OPN KD Hep3B and Huh7 caused a decrease in apoptosis.
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dramatically enhanced the apoptosis of cancer cells induced 
by ultraviolet radiation and chemotherapeutic agents [37]. 
In human cancer, sustained EGFR activation is commonly 
observed due to EGFR overexpression or the mutation 
of EGFR, leading to various tumor-promoting activities, 
including the inhibition of apoptosis [38, 39]. This anti-
apoptotic effect of EGFR is mediated by the MAPK/
ERK kinase (MEK)/MAPK signaling pathway in many 
types of normal cells as well as cancer cells [40, 41]. In 
agreement with previous studies, we found that WT mice 
showing a high EGFR expression level presented a lower 
apoptotic index in comparison to OPN KO mice, and that 
Figure 4: Changes in apoptosis in relation to OPN suppression. A. TUNEL assay of the Hep3B and Huh7. OPN KD Hep3B 
and Huh7 showed a higher frequency of TUNEL-positive cells than control cells, and rhOPN treatment of OPN KD Hep3B and Huh7 
reduced apoptotic cell death. B. Western blotting for the pro-apoptotic proteins PARP-1, caspase 9, and caspase 3, and the anti-apoptotic 
proteins Bcl-2 and Bcl-xL. The relative expression levels of apoptosis-related proteins in Hep3B (upper panels) and Huh7 (lower panels). 
The cleavage of PARP-1, caspase 9, and caspase 3 in OPN KD Hep3B and Huh7 from both cell lines was suppressed by supplementation 
with rhOPN, while the expression of anti-apoptotic proteins was upregulated. The results are presented as means ± SEMs (n=3 for each 
condition). * P < 0.05 versus OPN KD Hep3B and Huh7 under the corresponding culture conditions.
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OPN suppression led to decreased EGFR expression and 
phosphorylation of ERK, as well as increased apoptotic 
cell death in human HCC cells. The activity of EGFR can 
be regulated ligand-dependently or transcriptionally, and 
the latter is mediated by promoter-binding factor [14, 38]. 
Zenz et al. previously demonstrated that c-Jun, a member 
of the activator protein 1 family, played a crucial role in the 
transcriptional regulation of EGFR expression in a c-Jun 
conditional KO mice model [41]. They also showed that the 
lack of c-Jun ultimately led to apoptosis in keratinocytes. 
Based on this previous finding, we investigated the 
expression level of c-Jun depending upon OPN regulation, 
Figure 5: The regulatory effect of OPN on EGFR expression. A. Representative photomicrographs of immunohistochemistry 
for EGFR in liver tissue samples of WT and OPN KO mice at 36 weeks after DEN injection. EGFR expression in the cellular membrane 
of hepatocytes was stronger in WT mice than in OPN KO mice. Bar = 400 μm (inserts) B. RT-PCR and western blot for EGFR and c-Jun. 
OPN suppression caused a decrease in EGFR transcription, accompanied by the downregulation of nuclear c-Jun expression in the Hep3B 
and Huh7. The results are presented as SEMs (n=4). * P < 0.05 versus control cells. C. Western blot for EGFR and ERK. OPN KD cells 
Hep3B and Huh7 showed lower expression levels of EGFR and phosphorylated ERK1. The results are presented as means ± SEMs (n=4). 
* P < 0.05 versus control Hep3B and Huh7. D. Western blot for EGFR and ERK according to supplementation with rhOPN in OPN KD 
Hep3B and Huh7. The expression of EGFR and phosphorylated ERK was increased by rhOPN treatment in a time-dependent manner. The 
results are presented as means ± SEMs (n=3 for each condition). * P < 0.05 versus OPN KD Hep3B and Huh7.
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and found that c-Jun expression was suppressed by shRNA-
mediated OPN KD. Additionally, it may have been the 
case that c-Jun-mediated EGFR expression was regulated 
by secreted OPN, since supplemental rhOPN in OPN 
KD human HCC cells (not OPN overexpression) led to 
upregulated EGFR expression (Figure S3B). In combination 
with previous studies, our findings suggest that OPN is 
an important factor for inducing c-Jun-mediated EGFR 
transcription, resulting in the inhibition of apoptotic cell 
death.
In conclusion, we showed that OPN deficiency 
inhibited DEN-induced hepatic carcinogenesis in a mouse 
model, which could be linked with increased apoptotic cell 
death. In addition, in vitro study suggested the possibility 
that the anti-apoptotic effect of OPN may be related to the 
transcriptional upregulation of EGFR and the activation of 
the downstream molecule, p-ERK, which is mediated by 
c-Jun. Likewise, a positive correlation between OPN and 
EGFR expression was also identified in human HCC tissue 
as shown in a previous study [42]. In contrast to apoptosis, 
OPN suppression did not affect cell proliferation significantly 
(Figure S1). OPN and related signaling pathways are also 
involved in cell proliferation, invasion, and metastasis. 
Yoo et al. and Zhao et al. have previously described these 
roles of OPN in HCC using an in vitro and xenograft model 
[21, 33]. On the other hand, Fan et al. proposed that OPN 
deficiency aggravates DEN-induced hepatic carcinogenesis 
based on the size and multiplicity of liver tumor. It was a 
new perspective in the roles of OPN in carcinogenesis [43]. 
While they mainly focused on the roles of OPN in tumor 
progression because liver tumors developed in all mice at 
36 weeks after the injection of DEN, our mouse study could 
more logically explain the effect of OPN deficiency on 
tumor development considering many previous studies on 
the tumor-promoting effects of OPN. In the present study, we 
focused on the role of OPN in hepatocyte and cancer cells 
based on the histopathologic findings and IHC results from 
mouse and human HCC samples. However, further studies 
using liver-specific OPN KO mice rather than whole tissue-
OPN KO mice or a comparison of these two types of OPN 
KO mice could be useful for determining the role of OPN in 
hepatic carcinogenesis in greater detail because human HCC 
can be closely related to immune response against to cellular 
damage and infectious agents. Despite some limitations of 
this study, our findings suggest that OPN directly contributes 
to the development of HCC, which is positively correlated 
with the EGFR-mediated anti-apoptotic effect. Therefore, the 
induction of apoptosis in cancer cells through targeting OPN 
and EGFR may be a helpful approach for the prevention and 
treatment of human HCC.
Figure 6: IHC for OPN and EGFR in human HCC tissue samples. A. Representative photomicrographs of IHC for OPN and 
EGFR. Serially sectioned human HCC samples showing strong (a, d), moderate (b, e) and weak expression of OPN and EGFR (c, f). Bar 
= 400 μm (inserts). B. Correlations among OPN expression, pTNM, stages and EGFR expression.
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MATERIALS AND METHODS
Induction of HCC in mice
Male C57BL/6-Spp1tm1Blh (OPN-/-) (OPN KO) mice, 
purchased from Jackson Laboratory (Bar Harbor, ME, 
USA), and WT mice were divided into four groups (26 
and 36 weeks with either OPN KO or WT) with seven 
mice in each group as controls. The mice at 2 weeks old 
were injected with 25 mg/kg of DEN (Sigma Chemical 
Co., St. Louis, MO, USA) or vehicle intraperitoneally 
once to induce hepatic carcinogenesis. Mice in the control 
groups were not subjected to DEN injection. All mice were 
sacrificed 26 and 36 weeks after the injection of DEN. 
This study was approved by the Institutional Animal Care 
and Use Committee of Seoul National University, and all 
experiments were performed according to the Guide for 
Care and Use of Laboratory Animals published by the 
Institute for Laboratory Animal Research (Washington, 
DC, USA).
Immunohistochemical staining for OPN and 
TUNEL assay
In order to perform immunohistochemical staining 
for OPN in human and mouse tissues, replicate sections of 
paraffin-embedded liver tissue were mounted on silicon-
coated slides, dewaxed, and rehydrated, and antigen 
retrieval was then performed. The slides were incubated 
with anti-mouse or-human OPN antibody (1:100; R&D 
Systems, Minneapolis, MN, USA). Quantitation of 
immunoreactivity was performed using an H-scoring 
system, in which scores were calculated based on the 
intensity and number of positive cells according to the 
equation: Score = (3 × % intensely positive) + (2 × % 
moderately positive) + (1 × % weakly positive).
Apoptotic cell death in mouse tissue samples and 
Hep3B and Huh7 was determined through the terminal 
deoxynucleotidyl transferase dUTP nick-end labeling 
(TUNEL) assay using the Fluorecein FragEL DNA 
Fragmentation Detection kit (Calbiochem, Darmstadt, 
Germany).
Analysis of cell viability and flow cytometry for 
the apoptosis
To identify the effect of OPN on cell viability, a 
trypan blue exclusion assay was performed. After seeding 
on six-well plates at 1 × 105 cells/well and incubation for 
12, 24, and 48 hours with 1% fetal bovine serum (FBS), 
control and short-hairpin RNA (shRNA)-mediated OPN 
knockdown (KD) Hep3B and Huh7 cells were harvested, 
stained with trypan blue solution, and then counted using 
an inverted microscope.
Next, we performed anti-human OPN antibody 
(R&D Systems) or recombinant human OPN (rhOPN; 
R&D Systems) treatment on control and OPN KD Hep3B 
and Huh7 to investigate the effect of secreted OPN on cell 
viability. Before incubation with rhOPN or anti-human 
OPN antibody, the minimal cytotoxic concentrations were 
determined. After seeding on six-well plates at 1 × 105 
cells/well for 12 hours with 1% FBS, control Hep3B and 
Huh7 were incubated with 1 μg/mL of anti-human OPN 
antibody, and OPN KD Hep3B and Huh7 were incubated 
with 2 μg/mL of rhOPN for 12 hours. These cells were 
subjected to the trypan blue exclusion assay after being 
harvested.
For analysis of the apoptosis, control and OPN KD 
Hep3B and Huh7 treated with 2 μg/mL of rhOPN from 
the Hep3B and Huh7 lines were cultured at 2 × 105 cells/
well for 24 hours with 1% FBS, and harvested, washed, 
and re-suspended with cold phosphate-buffered saline. 
Apoptotic cell death was determined using an Annexin V 
Apoptosis Detection Kit FITC (eBioscience, San Diego, 
CA, USA). Cell-associated fluorescence was measured 
using a FACSCalibur apparatus (BD Bioscience). We 
also performed a TUNEL assay and a western blot for 
apoptosis-related proteins. After seeding on Lab-Tek 
Chamber slides (Thermo Fisher Scientific, Hudson, NH) at 
5 × 104 cells/well and incubation with 2 μg/mL of rhOPN 
for 24 hours, the TUNEL assay was performed on control, 
non-treated OPN KD and rhOPN-treated OPN KD Hep3B 
and Huh7. Similarly, control and OPN KD Hep3B and 
Huh7 incubated with 2 μg/mL of rhOPN from both cells 
were harvested and lysed at appropriate time points for 
western blotting.
Tissue microarray-based immunohistochemical 
staining of OPN and EGFR in human HCC 
tissue samples
Tissue-microarray (TMA) slides containing 58 
HCC samples were purchased from SuperBioChips 
Laboratories (Seoul, Korea, www.tissue-array.com). 
Immunohistochemistry (IHC) for OPN and EGFR on 
serially sectioned TMA slides was carried out using 
the BOND-MAX automated immunostainer (Leica 
Microsystems, Bannockburn, IL, USA) with the Bond 
Polymer Refine detection kit (Leica). Anti-OPN antibody 
(1:50; R&D Systems) or anti-EGFR antibody (1:100; 
Ventana Medical Systems, Oro Valley, AZ, USA) were 
employed as the primary antibody. Each stain was assessed 
according to the intensity (negative, 0; weak, 1; moderate, 
2; intense, 3) and area (none, 0; focal, 1; multifocal, 2; 
diffuse, 3) of positive cells. The overall grade of each stain 
was obtained by multiplying the area score by the intensity 
score (negative, 0; weak, 1 or 2; moderate, 3 or 4; intense, 
6 or 9).
Statistical analysis
All data were expressed as means ± standard 
errors (SEMs). Statistical analyses were performed using 
GraphPadPrism6 (version 6.0; GraphPad Software, San 
Oncotarget87229www.impactjournals.com/oncotarget
Diego, CA, USA). OPN expression in tumor tissue and 
non-tumor tissue samples from mouse and human liver 
was compared using the paired two-tailed Student’s t-
test. The relationship between the OPN genotype and the 
incidence of hepatocellular adenoma or carcinoma was 
analyzed using the chi-square test. Correlations between 
OPN expression and clinicopathological features or EGFR 
expression were analyzed using Spearman’s correlation 
test. Other data were analyzed using the unpaired two-
tailed Student’s t-test. P-values <0.05 were considered to 
indicate statistical significance.
Detailed Materials & Methods are described in 
Supplementary Data.
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